Global Neuroblastoma Treatment Market Growth (Status and Outlook) 2024-2030

Publication ID:

LPI02243212

Publication Date:

February 15, 2024

Pages:

111

Publisher:

LPI

Countries:

Global [1]

USD 3,660.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

The global Neuroblastoma Treatment market size was valued at US$ 434.3 million in 2023. With growing demand in downstream market, the Neuroblastoma Treatment is forecast to a readjusted size of US$ 557.5 million by 2030 with a CAGR of 3.6% during review period.
The research report highlights the growth potential of the global Neuroblastoma Treatment market. Neuroblastoma Treatment are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Neuroblastoma Treatment. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Neuroblastoma Treatment market.
Neuroblastoma treatment includes medical interventions and therapies used to manage neuroblastoma, a type of cancer that affects the sympathetic nervous system, typically occurring in young children.
The market for neuroblastoma treatment is driven by the need for effective and personalized therapies to improve survival rates and long-term outcomes for pediatric cancer patients. The market's growth is also influenced by ongoing research in neuroblastoma therapeutics and the development of targeted and immunotherapeutic approaches.
Key Features:
The report on Neuroblastoma Treatment market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Neuroblastoma Treatment market. It may include historical data, market segmentation by Type (e.g., Combination Chemotherapy, Monoclonal Antibody Therapy), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Neuroblastoma Treatment market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Neuroblastoma Treatment market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Neuroblastoma Treatment industry. This include advancements in Neuroblastoma Treatment technology, Neuroblastoma Treatment new entrants, Neuroblastoma Treatment new investment, and other innovations that are shaping the future of Neuroblastoma Treatment.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Neuroblastoma Treatment market. It includes factors influencing customer ' purchasing decisions, preferences for Neuroblastoma Treatment product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Neuroblastoma Treatment market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Neuroblastoma Treatment market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Neuroblastoma Treatment market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Neuroblastoma Treatment industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Neuroblastoma Treatment market.
Market Segmentation:
Neuroblastoma Treatment market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Combination Chemotherapy
Monoclonal Antibody Therapy
Vaccine Therapy
Chimeric Antigen Receptor T-Cell Immunotherapy
Oncolytic Virus Therapy
Segmentation by application
Hospitals
Clinics
Others
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Seattle Children鈥檚
CureSearch
Texas Children鈥檚
NANT
Sino Biopharmaceutical
Jiangsu Hengrui Medicine Co.,Ltd.
Fosun Pharmaceutical
Novartis
Juno Therapeutics
Kite Pharma
Adaptimmune

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Neuroblastoma Treatment Market Size 2019-2030
2.1.2 Neuroblastoma Treatment Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Neuroblastoma Treatment Segment by Type
2.2.1 Combination Chemotherapy
2.2.2 Monoclonal Antibody Therapy
2.2.3 Vaccine Therapy
2.2.4 Chimeric Antigen Receptor T-Cell Immunotherapy
2.2.5 Oncolytic Virus Therapy
2.3 Neuroblastoma Treatment Market Size by Type
2.3.1 Neuroblastoma Treatment Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Neuroblastoma Treatment Market Size Market Share by Type (2019-2024)
2.4 Neuroblastoma Treatment Segment by Application
2.4.1 Hospitals
2.4.2 Clinics
2.4.3 Others
2.5 Neuroblastoma Treatment Market Size by Application
2.5.1 Neuroblastoma Treatment Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Neuroblastoma Treatment Market Size Market Share by Application (2019-2024)
3 Neuroblastoma Treatment Market Size by Player
3.1 Neuroblastoma Treatment Market Size Market Share by Players
3.1.1 Global Neuroblastoma Treatment Revenue by Players (2019-2024)
3.1.2 Global Neuroblastoma Treatment Revenue Market Share by Players (2019-2024)
3.2 Global Neuroblastoma Treatment Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Neuroblastoma Treatment by Regions
4.1 Neuroblastoma Treatment Market Size by Regions (2019-2024)
4.2 Americas Neuroblastoma Treatment Market Size Growth (2019-2024)
4.3 APAC Neuroblastoma Treatment Market Size Growth (2019-2024)
4.4 Europe Neuroblastoma Treatment Market Size Growth (2019-2024)
4.5 Middle East & Africa Neuroblastoma Treatment Market Size Growth (2019-2024)
5 Americas
5.1 Americas Neuroblastoma Treatment Market Size by Country (2019-2024)
5.2 Americas Neuroblastoma Treatment Market Size by Type (2019-2024)
5.3 Americas Neuroblastoma Treatment Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Neuroblastoma Treatment Market Size by Region (2019-2024)
6.2 APAC Neuroblastoma Treatment Market Size by Type (2019-2024)
6.3 APAC Neuroblastoma Treatment Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Neuroblastoma Treatment by Country (2019-2024)
7.2 Europe Neuroblastoma Treatment Market Size by Type (2019-2024)
7.3 Europe Neuroblastoma Treatment Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Neuroblastoma Treatment by Region (2019-2024)
8.2 Middle East & Africa Neuroblastoma Treatment Market Size by Type (2019-2024)
8.3 Middle East & Africa Neuroblastoma Treatment Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Neuroblastoma Treatment Market Forecast
10.1 Global Neuroblastoma Treatment Forecast by Regions (2025-2030)
10.1.1 Global Neuroblastoma Treatment Forecast by Regions (2025-2030)
10.1.2 Americas Neuroblastoma Treatment Forecast
10.1.3 APAC Neuroblastoma Treatment Forecast
10.1.4 Europe Neuroblastoma Treatment Forecast
10.1.5 Middle East & Africa Neuroblastoma Treatment Forecast
10.2 Americas Neuroblastoma Treatment Forecast by Country (2025-2030)
10.2.1 United States Neuroblastoma Treatment Market Forecast
10.2.2 Canada Neuroblastoma Treatment Market Forecast
10.2.3 Mexico Neuroblastoma Treatment Market Forecast
10.2.4 Brazil Neuroblastoma Treatment Market Forecast
10.3 APAC Neuroblastoma Treatment Forecast by Region (2025-2030)
10.3.1 China Neuroblastoma Treatment Market Forecast
10.3.2 Japan Neuroblastoma Treatment Market Forecast
10.3.3 Korea Neuroblastoma Treatment Market Forecast
10.3.4 Southeast Asia Neuroblastoma Treatment Market Forecast
10.3.5 India Neuroblastoma Treatment Market Forecast
10.3.6 Australia Neuroblastoma Treatment Market Forecast
10.4 Europe Neuroblastoma Treatment Forecast by Country (2025-2030)
10.4.1 Germany Neuroblastoma Treatment Market Forecast
10.4.2 France Neuroblastoma Treatment Market Forecast
10.4.3 UK Neuroblastoma Treatment Market Forecast
10.4.4 Italy Neuroblastoma Treatment Market Forecast
10.4.5 Russia Neuroblastoma Treatment Market Forecast
10.5 Middle East & Africa Neuroblastoma Treatment Forecast by Region (2025-2030)
10.5.1 Egypt Neuroblastoma Treatment Market Forecast
10.5.2 South Africa Neuroblastoma Treatment Market Forecast
10.5.3 Israel Neuroblastoma Treatment Market Forecast
10.5.4 Turkey Neuroblastoma Treatment Market Forecast
10.5.5 GCC Countries Neuroblastoma Treatment Market Forecast
10.6 Global Neuroblastoma Treatment Forecast by Type (2025-2030)
10.7 Global Neuroblastoma Treatment Forecast by Application (2025-2030)

11 Key Players Analysis
11.1 Seattle Children鈥檚
11.1.1 Seattle Children鈥檚 Company Information
11.1.2 Seattle Children鈥檚 Neuroblastoma Treatment Product Offered
11.1.3 Seattle Children鈥檚 Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Seattle Children鈥檚 Main Business Overview
11.1.5 Seattle Children鈥檚 Latest Developments
11.2 CureSearch
11.2.1 CureSearch Company Information
11.2.2 CureSearch Neuroblastoma Treatment Product Offered
11.2.3 CureSearch Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 CureSearch Main Business Overview
11.2.5 CureSearch Latest Developments
11.3 Texas Children鈥檚
11.3.1 Texas Children鈥檚 Company Information
11.3.2 Texas Children鈥檚 Neuroblastoma Treatment Product Offered
11.3.3 Texas Children鈥檚 Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Texas Children鈥檚 Main Business Overview
11.3.5 Texas Children鈥檚 Latest Developments
11.4 NANT
11.4.1 NANT Company Information
11.4.2 NANT Neuroblastoma Treatment Product Offered
11.4.3 NANT Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 NANT Main Business Overview
11.4.5 NANT Latest Developments
11.5 Sino Biopharmaceutical
11.5.1 Sino Biopharmaceutical Company Information
11.5.2 Sino Biopharmaceutical Neuroblastoma Treatment Product Offered
11.5.3 Sino Biopharmaceutical Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Sino Biopharmaceutical Main Business Overview
11.5.5 Sino Biopharmaceutical Latest Developments
11.6 Jiangsu Hengrui Medicine Co.,Ltd.
11.6.1 Jiangsu Hengrui Medicine Co.,Ltd. Company Information
11.6.2 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Product Offered
11.6.3 Jiangsu Hengrui Medicine Co.,Ltd. Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Jiangsu Hengrui Medicine Co.,Ltd. Main Business Overview
11.6.5 Jiangsu Hengrui Medicine Co.,Ltd. Latest Developments
11.7 Fosun Pharmaceutical
11.7.1 Fosun Pharmaceutical Company Information
11.7.2 Fosun Pharmaceutical Neuroblastoma Treatment Product Offered
11.7.3 Fosun Pharmaceutical Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 Fosun Pharmaceutical Main Business Overview
11.7.5 Fosun Pharmaceutical Latest Developments
11.8 Novartis
11.8.1 Novartis Company Information
11.8.2 Novartis Neuroblastoma Treatment Product Offered
11.8.3 Novartis Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 Novartis Main Business Overview
11.8.5 Novartis Latest Developments
11.9 Juno Therapeutics
11.9.1 Juno Therapeutics Company Information
11.9.2 Juno Therapeutics Neuroblastoma Treatment Product Offered
11.9.3 Juno Therapeutics Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Juno Therapeutics Main Business Overview
11.9.5 Juno Therapeutics Latest Developments
11.10 Kite Pharma
11.10.1 Kite Pharma Company Information
11.10.2 Kite Pharma Neuroblastoma Treatment Product Offered
11.10.3 Kite Pharma Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Kite Pharma Main Business Overview
11.10.5 Kite Pharma Latest Developments
11.11 Adaptimmune
11.11.1 Adaptimmune Company Information
11.11.2 Adaptimmune Neuroblastoma Treatment Product Offered
11.11.3 Adaptimmune Neuroblastoma Treatment Revenue, Gross Margin and Market Share (2019-2024)
11.11.4 Adaptimmune Main Business Overview
11.11.5 Adaptimmune Latest Developments
12 Research Findings and Conclusion

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.

91制片厂